Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory panel will review NDA that includes more safety data for the antibiotic than the European MAA did.
You may also be interested in...
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.